Top

World Journal of Surgery

Published in:

Open Access 01-02-2016 | Original Scientific Report

Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast

Authors: J. W. Mituś, P. Blecharz, T. Walasek, M. Reinfuss, J. Jakubowicz, J. Kulpa

Published in: World Journal of Surgery | Issue 2/2016

Abstract

Background

Here, the treatment methods and results of patients with phyllodes tumor of the breast (PT) with distant metastases at a single institution are presented.

Methods

A retrospective analysis was performed on a group of 295 patients with PT treated from 1952 to 2010.

Results

Distant metastases developed in 37 (12.5 %) patients; 3/160 (1.9 %) patients had benign PT, 6/36 (16.7 %) were considered borderline, and 28/99 (28.3 %) had malignant PT. Most frequently, the metastases were located in the lungs; 28 (75.7 %), bone 7 (18.9 %), brain 4 (10.8 %), and liver 2 (5.4 %). Metastases occurred on overage 21 months (2–57) after surgery. Patients with lung metastases were generally treated with monochemotherapy or polychemotherapy. In one patient Testosterone and in two patients resection of metastases combined with Doxorubicin were used. Patients with bones or brain metastases were treated with palliative radiotherapy only or combined with Doxorubicin. The mean survival (MS) from diagnosis of distant metastases (DM) was 7 months (2–17). The longest mean survival in patients with bones metastases was 11.8 months, the worst survival was for patients with brain metastases—2.8 months. Hormone therapy appeared to have low efficacy (MS: 2 months) as well as monochemotherapy (MS: 3–5 months). Improved MS was obtained using Doxorubicin (7 months) and Doxorubicin with Cisplatin, Cyclophosphamide, or Ifosfamide (9 months).

Conclusion

The prognosis of patients with DM from PT is poor. The role of surgery and irradiation of such patients is very limited. There appears to be no role for the use of hormone therapy. This study showed that polychemotherapy with Doxorubicin and Ifosfamide suggest that it might be more effective than once thought.

Kim S, Kim JY, Kim do H, Jung WH, Koo JS (2013) Analysis of phyllodes tumor recurrence according to the histologic grade. Breast Cancer Res Treat 141(3):353–363. doi:10.1007/s10549-013-2684-x PubMedCrossRef

Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW (2007) Phyllodes tumors of the breast: natural history, diagnosis, and treatment. JNCCN 5(3):324–330PubMed

Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S et al (2013) Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Crit Rev Oncol/Hematol 88(2):427–436. doi:10.1016/j.critrevonc.2013.06.005 CrossRef

Mitus JW, Blecharz P, Reinfuss M, Kulpa JK, Skotnicki P, Wysocki WM (2013) Changes in the clinical characteristics, treatment options, and therapy outcomes in patients with phyllodes tumor of the breast during 55 years of experience. Med Sci Monit 19:1183–1187. doi:10.12659/MSM.889687 PubMedPubMedCentralCrossRef

Abdulcadir D, Nori J, Meattini I, Giannotti E, Boeri C, Vanzi E et al (2014) Phyllodes tumours of the breast diagnosed as B3 category on image-guided 14-gauge core biopsy: analysis of 51 cases from a single institution and review of the literature. Eur J Surg Oncol 40(7):859–864. doi:10.1016/j.ejso.2014.02.222 PubMedCrossRef

Kapiris I, Nasiri N, A’Hern R, Healy V, Gui GP (2001) Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol 27(8):723–730. doi:10.1053/ejso.2001.1207 PubMedCrossRef

Mitus J, Reinfuss M, Mitus JW, Jakubowicz J, Blecharz P, Wysocki WM et al (2014) Malignant phyllodes tumor of the breast: treatment and prognosis. Breast J 20(6):639–644. doi:10.1111/tbj.12333 PubMedCrossRef

Tse GM, Niu Y, Shi HJ (2010) Phyllodes tumor of the breast: an update. Breast Cancer 17(1):29–34. doi:10.1007/s12282-009-0114-z PubMedCrossRef

Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL et al (2005) Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol 91(3):185–194. doi:10.1002/jso.20334 PubMedCrossRef

10.

Cheng SP, Chang YC, Liu TP, Lee JJ, Tzen CY, Liu CL (2006) Phyllodes tumor of the breast: the challenge persists. World J Surg 30(8):1414–1421. doi:10.1007/s00268-005-0786-2 PubMedCrossRef

11.

Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE et al (2000) Primary treatment of cystosarcoma phyllodes of the breast. Cancer 89(7):1502–1511PubMedCrossRef

12.

Reinfuss M, Mitus J, Duda K, Stelmach A, Rys J, Smolak K (1996) The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 77(5):910–916PubMedCrossRef

13.

Barth RJ Jr, Wells WA, Mitchell SE, Cole BF (2009) A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol 16(8):2288–2294. doi:10.1245/s10434-009-0489-2 PubMedCrossRef

14.

Abdalla HM, Sakr MA (2006) Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast. J Egypt Natl Cancer Inst 18(2):125–133

15.

Burton GV, Hart LL, Leight GS Jr, Iglehart JD, McCarty KS Jr, Cox EB (1989) Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy. Cancer 63(11):2088–2092PubMedCrossRef

16.

Hawkins RE, Schofield JB, Wiltshaw E, Fisher C, McKinna JA (1992) Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. Cancer 69(9):2271–2275PubMedCrossRef

17.

Park IH, Kwon Y, Kim EA, Lee KS, Ro J (2009) Major response to sunitinib (Sutene) in metastatic malignant phyllodes tumor of breast. Investig New Drugs 27(4):387–388. doi:10.1007/s10637-008-9195-3 CrossRef

18.

Kessinger A, Foley JF, Lemon HM, Miller DM (1972) Metastatic cystosarcoma phyllodes: a case report and review of the literature. J Surg Oncol 4(2):131–147PubMedCrossRef

19.

Reinfuss M, Mitus J, Smolak K, Stelmach A (1993) Malignant phyllodes tumours of the breast. A clinical and pathological analysis of 55 cases. Eur J Cancer 29A(9):1252–1256PubMedCrossRef

20.

Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW et al (2007) Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 14(10):2961–2970. doi:10.1245/s10434-007-9439-z PubMedCrossRef

21.

Guillot E, Couturaud B, Reyal F, Curnier A, Ravinet J, Lae M et al (2011) Management of phyllodes breast tumors. Breast J 17(2):129–137. doi:10.1111/j.1524-4741.2010.01045.x PubMedCrossRef

22.

Belkacemi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magne N, Malard Y et al (2008) Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys 70(2):492–500. doi:10.1016/j.ijrobp.2007.06.059 PubMedCrossRef

23.

Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK (2006) Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer 107(9):2127–2133. doi:10.1002/cncr.22228 PubMedCrossRef

24.

Fou A, Schnabel FR, Hamele-Bena D, Wei XJ, Cheng B, El Tamer M et al (2006) Long-term outcomes of malignant phyllodes tumors patients: an institutional experience. Am J Surg 192(4):492–495. doi:10.1016/j.amjsurg.2006.06.017 PubMedCrossRef

25.

Reinfuss M, Mitus J, Stelmach A (1995) Phyllodes tumor of the breast. Strahlentherapie und Onkologie 171(1):5–11PubMed

26.

Asoglu O, Ugurlu MM, Blanchard K, Grant CS, Reynolds C, Cha SS et al (2004) Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors. Ann Surg Oncol 11(11):1011–1017. doi:10.1245/ASO.2004.02.001 PubMedCrossRef

27.

Hawkins RE, Schofield JB, Fisher C, Wiltshaw E, McKinna JA (1992) The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer 69(1):141–147PubMedCrossRef

28.

Riepl M, Strnad V (1994) Radiochemotherapy in the liver metastases of cystosarcoma phyllodes. Strahlentherapie und Onkologie 170(11):668–672PubMed

29.

de Roos WK, Kaye P, Dent DM (1999) Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast. Br J Surg 86(3):396–399. doi:10.1046/j.1365-2168.1999.01035.x PubMedCrossRef

30.

National Comprehensive Cancer Network. NCCN Clinical practice guidelines in Oncology. Soft tissue sarcoma. 2014 Accessed NCCN.org Version 2

31.

Jardim DL, Conley A, Subbiah V (2013) Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. Orphanet J Rare Dis 8:112. doi:10.1186/1750-1172-8-112 PubMedPubMedCentralCrossRef

Title: Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast
Authors: J. W. Mituś
P. Blecharz
T. Walasek
M. Reinfuss
J. Jakubowicz
J. Kulpa
Publication date: 01-02-2016
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 2/2016
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-015-3262-7

ACC 2024 Congress

Springer Medicine

Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2016

Is the Reluctance for the Implantation of Right Donor Kidneys Justified?

Presentation and Outcomes After Surgery for Primary Hyperparathyroidism During an 18-Year Period

Augmented Reality Guidance for the Resection of Missing Colorectal Liver Metastases: An Initial Experience

A Systematic Review of Patient-reported Outcomes in Randomized Controlled Trials of Unplanned General Surgery

Management of Retropharyngeal Node Metastases from Thyroid Carcinoma: Reply

Clinical Significance of Multiple Pulmonary Metastasectomy for Hepatocellular Carcinoma